Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2014

01-07-2014 | Focussed Research Review

Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients

Authors: Zaima Mazorra Herrera, Tania Crombet Ramos

Published in: Cancer Immunology, Immunotherapy | Issue 7/2014

Login to get access

Abstract

Cancer vaccines contain tumor antigens in a pro-inflammatory context with the purpose to generate potent antitumor immune responses. However, tumor cells develop different immunosuppressive mechanisms that limit the effectiveness of an anticancer immune response. Therefore, therapeutic vaccine treatment alone is usually not sufficient to generate tumor regression or survival improvement, especially in the advanced disease scenario in which most clinical studies have been conducted. Combining cancer vaccines with different anticancer therapies such as chemotherapy, radiotherapy and other immunotherapeutic agents has had different levels of success. However, the combination of cancer vaccines with different mechanisms of action has not been explored in clinical trials. To address this issue, the current review summarizes the main clinical and immunological results obtained with two different therapeutic vaccines used in advanced non-small-cell lung cancer patients, inducing an immune response against epidermal growth factor (CIMAvax-EGF) and NGcGM3 ganglioside (racotumomab). We also discuss preliminary findings obtained in a trial of combination of these two vaccines and future challenges with these therapies.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef
2.
Kostyleva OI, Gershtein ES, Dykhno A, Polotskii BE, Vasil’ev AV, Kushlinskii NE (1999) Clinical and prognostic importance of the expression of epidermal growth factor receptors in non-small-cell lung carcinoma. Biull Eksp Biol Med 127:446–449PubMedCrossRef
3.
Blanco R, Rengifo CE, Cedeño M, Frometa M, Rengifo E, Carr A (2012) Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Pathol Res Int 2012:235418CrossRef
4.
Hayashi N, Chiba H, Kuronuma K et al (2013) Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 104:43–47PubMedCrossRef
5.
de Leon J, Fernández A, Mesa C, Clavel M, Fernández LE (2006) Role of tumour-associated N-glycolyated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 55:443–450PubMedCrossRef
6.
Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373–389
7.
Chapman PB (2003) Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 4:710–715PubMed
8.
Chong G, Bhatnagar A, Cunningham D et al (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 17:437–442PubMedCrossRef
9.
Reinartz S, Kohler S, Schlebusch H et al (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10:1580–1587PubMedCrossRef
10.
Sabbatini P, Harter P, Scambia G et al (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J Clin Oncol 31:1554–1561PubMedCrossRef
11.
Giaccone G, Debruyne C, Felip E et al (2005) Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23:6854–6864PubMedCrossRef
12.
Irie A, Suzuki A (1998) CMP-N-Acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 248:330–333PubMedCrossRef
13.
Marquina G, Waki H, Fernández LE, Kon K, Carr A, Valiente O, Pérez R, Ando S (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165–5171PubMed
14.
van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G (2009) Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9:180PubMedCentralPubMedCrossRef
15.
Díaz Y, González A, López A, Pérez R, Vázquez AM, Montero E (2009) Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 58:1117–1128PubMedCrossRef
16.
Alfonso M, Díaz A, Hernández AM, Pérez A, Rodriguez E, Bitton R, Pérez R, Vázquez AM (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168:2523–2529PubMedCrossRef
17.
Díaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Pérez R, Vázquez AM (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107:80–89PubMedCrossRef
18.
Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vázquez AM, Fainboim L (2006) Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29:215–223PubMedCrossRef
19.
Soriano JL, Batista N, Santiesteban E et al (2011) Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int J Breast Cancer 2011:710292PubMedCentralPubMedCrossRef
20.
Yin J, Hashimoto A, Izawa M et al (2006) Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 66:2937–2945PubMedCrossRef
21.
Alfonso S, Díaz RM, de la Torre A et al (2007) 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6:1847–1852PubMedCrossRef
22.
Hernández AM, Toledo D, Martínez D et al (2008) Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 181:6625–6634PubMedCrossRef
23.
Pavelic K, Banjac Z, Pavelic J, Spaventi S (1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133–1137PubMed
24.
Masago K, Fujita S, Hatachi Y, Fukuhara A, Sakuma K, Ichikawa M, Kim YH, Mio T, Mishima M (2008) Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 99:2295–2301PubMedCrossRef
25.
Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Hauptmann M, de Visser KE, van den Heuvel MM, Linn SC (2010) Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 5:1939–1948PubMedCrossRef
26.
27.
Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A (2011) EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci 16:1962–1972CrossRef
28.
Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531PubMedCrossRef
29.
Perol M, Chouaid C, Perol D et al (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30:3516–3524PubMedCrossRef
30.
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRef
31.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef
32.
Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedCrossRef
33.
Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529PubMedCrossRef
34.
González SB, Suárez E, Beausoleil I, Perez O, Lastre M et al (1996) Induction of immune recognition of self-epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vac Res 5:233–244
35.
Rodriguez PC, González I, González A, Avellanet J, Lopez A, Pérez R, Lage A, Montero E (2008) Priming and boosting determinants on the antibody response to an epidermal growth factor-based cancer vaccine. Vaccine 26:4647–4654PubMedCrossRef
36.
González G, Lage A (2007) Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 7:229–241PubMedCrossRef
37.
Hirsch FR, Herbst RS, Olsen C et al (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26:3351–3357PubMedCentralPubMedCrossRef
38.
Rodriguez PC, Rodriguez G, González G, Lage A (2010) Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 12:17–23PubMed
39.
Neninger Vinageras E, de la Torre A, Osorio Rodriguez M et al (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26:1452–1458PubMedCrossRef
40.
García B, Neninger E, de la Torre A et al (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:840–846PubMedCrossRef
41.
Stein WD, Gulley JL, Schlom J et al (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907–917PubMedCrossRef
42.
van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355–366PubMedCentralPubMedCrossRef
43.
Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206–213PubMedCrossRef
44.
O’Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110:2614–2627PubMedCrossRef
45.
Chou HH, Hayakawa T, Diaz S et al (2002) Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc Natl Acad Sci USA 99:11736–11741PubMedCentralPubMedCrossRef
46.
Jo M, Thomas KS, O’Donnell DM, Gonias SL (2003) Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem 278:1642–1646PubMedCrossRef
47.
Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932–943PubMedCrossRef
48.
Wang XQ, Sun P, Go L, Koti V, Fliman M, Paller AS (2006) Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling. J Invest Dermatol 126:2687–2696PubMedCrossRef
49.
de Leon J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, Fernández LE (2008) Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4 + CD25- effector and naturally occurring CD4 + CD25 + regulatory T cells function. Int Immunol 20:591–600PubMedCrossRef
50.
Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD (2012) Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS ONE 7:e31962PubMedCentralPubMedCrossRef
51.
Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868PubMedCrossRef
52.
Brode S, Cooke A (2008) Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28:109–126PubMedCrossRef
Metadata
Title
Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients
Authors
Zaima Mazorra Herrera
Tania Crombet Ramos
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 7/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1552-9

Other articles of this Issue 7/2014

Cancer Immunology, Immunotherapy 7/2014 Go to the issue

Focussed Research Review

Monitoring the immune competence of cancer patients to predict outcome

Original Article

Chronic intake of high fish oil diet induces myeloid-derived suppressor cells to promote tumor growth

Original Article

Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells

Original Article

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Focussed Research Review

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

Meeting Report

Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14–16, 2013
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits